# Breast cancer ADC treatment registry

Source: https://onco.cc/trials/nct06774027/  
OnCo record `nct06774027` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This registry follows people receiving approved antibody-linked drugs as part of routine breast cancer care. It studies outcomes when these drugs are used in sequence without assigning the treatment.

## Summary

This registry follows people receiving approved antibody-linked drugs as part of routine breast cancer care. It studies outcomes when these drugs are used in sequence without assigning the treatment.

Observational study registered as NCT06774027, sponsored by University of California, San Francisco. Registry enrollment is 100 participants (estimated). Registry status checked October 10, 2026: recruiting. UCSF lists this study as open to eligible people; local availability and overall registry status are separate. See the registry for full eligibility and current sites.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-10
- Also known as: Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
- Tags: ucsf-breast-coverage; observational
- Registry id: NCT06774027
- Phase: observational
- Setting: Metastatic HER2-negative breast cancer treated with approved antibody-drug conjugates
- Sponsor: University of California, San Francisco

## Sources

- ClinicalTrials.gov NCT06774027: https://clinicaltrials.gov/study/NCT06774027
- UCSF study listing and local availability: https://clinicaltrials.ucsf.edu/trial/NCT06774027

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)

---
JSON: https://onco.cc/api/v1/entities/nct06774027.json